What 17 Analyst Ratings Have To Say About CRISPR Therapeutics
Portfolio Pulse from Benzinga Insights
In the last 3 months, 17 analysts have offered 12-month price targets for CRISPR Therapeutics (NASDAQ:CRSP), with an average price target of $66.29, up 12.99% from the previous average of $58.67. The ratings include 5 bullish, 4 somewhat bullish, 7 indifferent, and 1 somewhat bearish.
June 09, 2023 | 3:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CRISPR Therapeutics has an average 12-month price target of $66.29, up 12.99% from the previous average, with a majority of analysts having bullish or somewhat bullish ratings.
The average 12-month price target for CRISPR Therapeutics has increased by 12.99% from the previous average, indicating a positive sentiment among analysts. With a majority of analysts having bullish or somewhat bullish ratings, this suggests a potential short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100